Zacks: Brokerages Anticipate Caladrius Biosciences Inc (CLBS) Will Announce Earnings of -$0.38 Per Share

Equities research analysts forecast that Caladrius Biosciences Inc (NASDAQ:CLBS) will post ($0.38) earnings per share for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have made estimates for Caladrius Biosciences’ earnings. Caladrius Biosciences posted earnings per share of ($0.40) in the same quarter last year, which would suggest a positive year over year growth rate of 5%. The company is expected to announce its next quarterly earnings report on Thursday, March 28th.

According to Zacks, analysts expect that Caladrius Biosciences will report full-year earnings of ($1.75) per share for the current year, with EPS estimates ranging from ($1.81) to ($1.69). For the next year, analysts anticipate that the firm will report earnings of ($2.03) per share, with EPS estimates ranging from ($2.36) to ($1.69). Zacks’ EPS calculations are a mean average based on a survey of sell-side analysts that that provide coverage for Caladrius Biosciences.

Caladrius Biosciences (NASDAQ:CLBS) last posted its quarterly earnings data on Thursday, November 8th. The biotechnology company reported ($0.36) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.56) by $0.20.

Several research firms have recently commented on CLBS. Chardan Capital reissued a “buy” rating on shares of Caladrius Biosciences in a research note on Wednesday, August 29th. Zacks Investment Research raised shares of Caladrius Biosciences from a “hold” rating to a “buy” rating and set a $6.25 price target on the stock in a research note on Wednesday, September 12th. Finally, HC Wainwright increased their price target on shares of Caladrius Biosciences to $15.00 and gave the company a “buy” rating in a research note on Monday, September 10th.

A number of hedge funds have recently made changes to their positions in CLBS. Renaissance Technologies LLC boosted its stake in Caladrius Biosciences by 42.9% in the third quarter. Renaissance Technologies LLC now owns 280,864 shares of the biotechnology company’s stock valued at $1,657,000 after acquiring an additional 84,301 shares during the last quarter. Dimensional Fund Advisors LP bought a new position in Caladrius Biosciences in the first quarter valued at approximately $197,000. Finally, JPMorgan Chase & Co. bought a new position in Caladrius Biosciences in the first quarter valued at approximately $110,000. 7.64% of the stock is currently owned by hedge funds and other institutional investors.

Shares of CLBS traded down $0.01 during mid-day trading on Friday, hitting $4.99. 14,713 shares of the company traded hands, compared to its average volume of 23,336. Caladrius Biosciences has a one year low of $3.04 and a one year high of $11.65. The stock has a market capitalization of $49.11 million, a P/E ratio of -2.80 and a beta of 1.22.

Caladrius Biosciences Company Profile

Caladrius Biosciences, Inc operates as a global healthcare company, which engages in developing cellular therapies that repair damaged tissue, cells and organs and restore their normal function. It is pursuing the preservation and enhancement of human health globally through the development of cell based therapeutics that prevent, treat or cure disease.

Read More: Is a Roth IRA right for you?

Get a free copy of the Zacks research report on Caladrius Biosciences (CLBS)

For more information about research offerings from Zacks Investment Research, visit

Receive News & Ratings for Caladrius Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Caladrius Biosciences and related companies with's FREE daily email newsletter.


Leave a Reply

share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on reddit